SSY Group (2005) investor relations material

Executive summary

• Revenue rose 9.9% year-over-year to HK$2,360.6 million, driven by strong growth in intravenous infusion solutions and bulk pharmaceuticals.

• Net profit attributable to equity shareholders increased 13.0% to HK$320.3 million, with EPS at HK$0.1107, up from HK$0.0962.

• Interim dividend of HK$0.055 per share declared, up 10% from last year.

• The Group maintained a sound liquidity position and low-risk capital structure.

Financial highlights

• Gross profit margin slightly decreased to 41.2% from 41.5% year-over-year.

• Operating profit rose 20.1% to HK$445.3 million, with operating margin improving to 18.9%.

• Net finance costs nearly doubled to HK$69.4 million due to lower interest income and foreign exchange loss.

• Current ratio stable at 1.87; gearing ratio improved to 21.9% from 24.1% at year-end.

Outlook and guidance

• Focus on strengthening operations, stabilizing expectations, and integrating innovation, product, supply, and value chains.

• Plans to accelerate market access, expand exports, and enhance R&D for high-value-added products.

• Continued investment in infrastructure and new product industrialization to drive sustainable growth.